A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic

Mohsen Gholi-Nataj¹, Shahab Rafieian², Maedeh Barahman³, Ahmad Shirinzadeh-Dastgiri⁴, Mohammad Vakili⁵, Reza Ershadi⁶, Hamid Mirjalili⁷, Fatemeh Asadian⁸, Hossein Neamatzadeh⁹

Show Less

¹ Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

² Department of Thoracic Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

³ Firoozgar Clinical Research Development Center (FCRDC), Firoozgar Hospital University of Medical Sciences, Tehran, Iran

⁴ Department of Surgery, Faculty of Medicine, Shohadaye Hafte-e-tie hospital University of Medical Sciences, Tehran, Iran

⁵ Department of Surgery, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

⁶ Department of Thoracic Surgery, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran

⁷ Department of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran

⁸ Department of Emergency Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

⁹ Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

EJMO 2022, 6(1), 73–82; https://doi.org/10.14744/ejmo.2022.50535

Submitted: 22 January 2022 | Accepted: 20 February 2022 | Published: 9 March 2022

© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

Abstract

Objectives: Cancer patients were found to be at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced more adverse outcomes. The objective of this meta-analysis was to estimate the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic.

Methods: A comprehensive search was carried out on PubMed, Web of Science, Scopus, MedRxiv, SciELO, SID, CNKI, and Wanfang databases to retrieve all relevant publications. All cross-sectional studies and consecutive case series on cancer patients with SARS-CoV-2 infection were selected. A total of 28 studies including 5400 infected cancer patients and 767 lung cancer patients with COVID-19 were included.

Results: Combined data indicated that the prevalence of lung cancer patients with SARS-CoV-2 infection was 15.2% (95% CI, 0.111–0.205) overall. Stratified analysis by ethnicity showed that the prevalence was 16.4% and 15.4% in Asian and Caucasian lung cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that the prevalence was highest in China (19.3.0%) followed by France (12.6%), the UK (10.7%), and the USA (8.3%).

Conclusion: This meta-analysis revealed that the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 15.2%.

Keywords

SARS-CoV-2

COVID-19

lung cancer

infection

meta-analysis

Conflict of interest

None declared.

References

1. Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, Abbasi H, Mirjalili SR, Behforouz A, et al. Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: a review. Fetal Pediatr Pathol 2020;39:246–50.
2. Noorishadkam M, Lookzadeh MH, Mazaheri M, Mirjalili SR, Bahrami R, Asadian F, et al. Coronavirus Disease 2019 (COVID-19) and late pregnancy loss in infected pregnant women: a mini review. WJPN 2020;2:67–70.
3. Mirjalili H, Dastgheib SA, Shaker SH, Bahrami R, Mazaheri M, Sadr-Bafghi SMH, et al. Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis. J Diabetes Metab Disord 2021;20:905–17.
4. Sayad S, Ahmadi SAY, Nekouian R, Panahi M, Anbari K. Epidemiological and pathological characteristics of post-surgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study. Arch Oncol 2020;26:6–9.
5. Coronavirus Disease (COVID-19) Situation Reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed Apr 5, 2021.
6. Cancarevic I, Tathineni P, Malik BH. Coronavirus Disease 2019 (COVID-19) in cancer patients. Cureus 2020;12:e7835.
7. Leung TF, Wong GW, Hon KL, Fok TF. Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management. Paediatr Respir Rev 2003;4:334–9
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
9. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARSCoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91–5.
10. de Marinis F, Attili I, Morganti S, Stati V, Spitaleri G, Gianoncelli L, et al. Results of multilevel containment measures to better protect lung cancer patients from COVID-19: The IEO model. Front Oncol 2020;10:665.
11. Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, et al. The immuno-oncological challenge of COVID-19. Nat Cancer 2020;1:946–4.
12. Milionis C, Milioni SO. A brief analysis and hypotheses about the risk of COVID-19 for people with type 1 and type 2 diabetes mellitus. J Diabetes Metab Disord 2020;19:2035–9.
13. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther 2020;5:128.
14. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, et al. Immunosenescence and its hallmarks: how to oppose aging strategically? a review of potential options for therapeutic intervention. Front Immunol 2019;10:2247.
15. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783–91.
16. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020;43:452–5.
17. Sayad S, Ahmadi SAY, Moradi M, Nekouian R, Anbari K, Shahsavar F. A meta-analysis on diagnostic accuracy of serum HLA-G level in breast cancer. Expert Rev Precis Med Drug Dev 2020;5:109–14.
18. Jyotsana N, King MR. The impact of COVID-19 on cancer risk and treatment. Cel Mol Bioeng 2020;13:285–91.
19. Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and cancer: a comprehensive review. Curr Oncol Rep 2020;22:53.
20. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al; COVID-19 and cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395:1907–18.
21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
22. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARSCoV-2 (Covid-19). J Clin Med 2020;9:841.
23. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction 2021;116:1319–68.
24. Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8:542–4.
25. Liao Z, Rivin Del Campo E, Salem A, Pang Q, Liu H, Lopez Guerra JL. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer 2020;146:230–5.
26. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: A meta-analysis of patient data. JCO Global Oncology 2020:799–808.
27. Baghestani AR, Shahmirzalou P, Sayad S, Akbari ME, Zayeri F. Comparison cure rate models by DIC criteria in breast cancer data. Asian Pac J Cancer Prev 2018;19:1601–6.
28. Lee LYW, Cazier JB, Starkey T, Turnbull CD, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395:1919–26.
29. Mahmood TB, Chowdhury AS, Hossain MU, Hasan M, Mizan S, Aakil MM, et al. Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. Curr Res Microb Sci 2021;2:100022.
30. Jarahzadeh MH, Asadian F, Farbod M, Meibodi B, Abbasi H, Jafari M, et al. Cancer and Coronavirus Disease (COVID-19): comorbidity, mechanical ventilation, and death risk. J Gastrointest Cancer 2021;52:80–4.
31. Antikchi MH, Neamatzadeh H, Ghelmani Y, Jafari-Nedooshan J, Dastgheib SA, Kargar S, et al. The risk and prevalence of COVID-19 infection in colorectal cancer patients: a systematic review and meta-analysis. J Gastrointest Cancer 2021;52:73–9.
32. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, AcunaVillaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020;10:935–41.
33. Ahmadi SAY, Sayad S, Shahsavar F, Nekouian R, Panahi M, Sayad S, et al. Expression of angiogenesis-related genes in a group of Iranian cases of breast cancer. Curr Pharmacogenomics Person Med 2021;17:197–205.
34. Behtash N, Zarchi MK, Deldar M. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran. Asian Pac J Cancer Prev 2009;10:613–8.
35. Mousavi A, Karimi Zarchi M, Gilani MM, Behtash N, Ghaemmaghami F, Shams M, et al. Radical hysterectomy in the elderly. World J Surg Oncol 2008;6:38.
36. Ghaemmaghami F, Zarchi MK, Gilani MM, Mousavi A, Behtash N, Ghasemi M. Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in Iran. Asian Pac J Cancer Prev 2008;9:421–6.
37. Khoram-Abadi KM, Forat-Yazdi M, Kheirandish S, Saeidi N, Za-rezade Z, Mehrabi N, et al. DNMT3B -149 C>T and -579 G>T polymorphisms and risk of gastric and colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev 2016; 17:3015–20.
38. Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020;126:4023–31.
39. Wang J, Song Q, Chen Y, Wang Z, Chu Q, Gong H, et al. Systematic investigations of COVID-19 in 283 cancer patients. MedRxiv. 2020 May 3. Doi: https://doi.org/10.1101/2020.04.28.2008. [Epub ahead of print].
40. Ali J, Sajjad K, Farooqi AR, Aziz MT, Rahat A, Khan S. COVID19-positive cancer patients undergoing active anticancer treatment: An analysis of clinical features and outcomes. Hematol Oncol Stem Cell The. 2021;14:311–7.
41. Aznab M. Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic. Int J Clin Oncol 2020;25:1581–6.
42. Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. Cancer Res 2020;80:CT403.
43. Basse C, Diakite S, Servois V, Frelaut M, Noret A, Bellesoeur A, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. JNCI Cancer Spectr 2021;5:pkaa090.
44. Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARSCOV-2 on RT-PCR. Eur J Cancer 2020;135:251–9.
45. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al; TERAVOLT investigators. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020;21:914–22.
46. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020;26:1218–23.
47. Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol 2020;38:3538–46.
48. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020;92:2067–73.
49. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020;31:1088–9.
50. Kabarriti R, Brodin NP, Maron MI, Tomé WA, Halmos B, Guha C, et al. Extent of prior lung irradiation and mortality in COVID-19 patients with a cancer history. Adv Radiat Oncol 2020;5:707– 10.
51. Russell B, Moss C, Papa S, Irshad S, Ross P, Spicer J, et al. Factors affecting COVID-19 Outcomes in cancer patients: a first report from Guy's Cancer Center in London. Front Oncol 2020;10:1279.
52. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol2020;21:1309–16.
53. Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. Eur J Cancer 2020;139:181–7.
54. Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol 2020;16:1425–32.
55. Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo-Loureiro A, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 2020;135:242–50.
56. de Melo AC, Thuler LCS, da Silva JL, de Albuquerque LZ, Pecego AC, Rodrigues L de OR, et al. Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute. PLos One 2020;15:e0241261.
57. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904–13.
58. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:893– 903.
59. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020;6:1108–10.
60. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.
61. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31:894–901.
62. Zhang Y, Li M, Gan L, Li B. Analysis of clinical characteristics of 5 tumor patients with coronavirus disease 2019. Guangdong Med J 2020;41.
63. Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study. J Infect 2020;81:318–56.
64. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395:1763–70.
65. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: Prospective cohort study. BMJ 2020;369:m1923.
66. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020;217:e20200678.
67. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39:405–7.
68. Peravali M, Joshi I, Ahn J, Kim C. A Systematic review and meta-analysis of clinical characteristics and outcomes in patients with lung cancer with coronavirus disease 2019. JTO Clin Res Rep 2021;2:100141.
69. Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol 2020;31:1386–96.
70. Venkatesulu BP, Chandrasekar VT, Girdhar P, Advani P, Sharma A, Elumalai T, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv. 2020 May 29. Doi: 10.1101/2020.05.27.20115303. [Epub ahead of print].
71. Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: Evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol 2020;153:103032.

Previous article in this issue

Next article in this issue

Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing